Inherited mutations in breast cancer genes-risk and response

Journal of Mammary Gland Biology and Neoplasia

Volumn 16, Issue 1, 2011, Pages 3-15

  Shuen, Andrew Y ^a   Foulkes, William D ^a,b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

BRCA1; BRCA2; Breast cancer susceptibility genes; Cisplatin; PARP inhibitors

Indexed keywords

ANTHRACYCLINE; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; CISPLATIN; MRE11 PROTEIN; NIBRIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RAD50 PROTEIN;

ALLELE; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; COMPLEX FORMATION; DNA DAMAGE; DRUG POTENTIATION; DRUG TARGETING; FAMILIAL CANCER; FANCONI ANEMIA; GENE FUNCTION; GENE MUTATION; GENETIC SCREENING; GENOME ANALYSIS; MULTIFACTORIAL INHERITANCE; PENETRANCE; POPULATION GENETICS; SUMOYLATION; TRIPLE NEGATIVE BREAST CANCER; UBIQUITINATION;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA DAMAGE; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION;

EID: 79959605900     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-011-9213-5     Document Type: Article

References (129)

1. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4(9):665-76. (Pubitemid 39215065)
2. Ford D et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62 (3):676-89. (Pubitemid 28164626)
3. Smith P et al. A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosom Cancer. 2006;45(7):646-55. (Pubitemid 43727152)
4. Pharoah PDP et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008;358(26):2796-803.
5. Manolio TA et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747-53.
6. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol. 2010;11(2):138-48.
7. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010;11(3):196-207.
8. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31(6): 961-7.
9. Chinnadurai G. The transcriptional corepressor CtBP: a foe of multiple tumor suppressors. Cancer Res. 2009;69(3):731-4.
10. Zhang Q, Piston DW, Goodman RH. Regulation of corepressor function by nuclear NADH. Science. 2002;295(5561):1895-7. (Pubitemid 34214127)
11. Fjeld CC, Birdsong WT, Goodman RH. Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci USA. 2003;100(16):9202-7. (Pubitemid 37033907)
12. Kolas NK et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science. 2007;318(5856):1637-40. (Pubitemid 350233664)
13. Huen MSY et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell. 2007;131(5):901-14.
14. Doil C et al. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell. 2009;136(3):435-46.
15. Morris JR et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature. 2009;462 (7275):886-90.
16. Galanty Y et al. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature. 2009;462(7275):935-9.
17. Yang H et al. The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction. Nature. 2005;433(7026):653-7. (Pubitemid 40283000)
18. San Filippo J et al. Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide. J Biol Chem. 2006;281(17):11649-57.
19. Jensen RB et al. Purified human BRCA2 stimulates RAD51- mediated recombination. Nature. 2010;467(7316):678-83.
20. Thorslund T et al. The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. Nat Struct Mol Biol. 2010;17(10):1263-5.
21. Liu J, Doty T, Gibson B, Heyer W. Human BRCA2 protein promotes RAD51 filament formation on RPA-covered singlestranded DNA. Nat Struct Mol Biol. 2010;17(10):1260-2.
22. Metcalfe KA et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2010;28 (3):387-91.
23. Antoniou A et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-30. (Pubitemid 36530000)
24. Simchoni S et al. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. ProcNatlAcad Sci USA. 2006;103(10):3770-4. (Pubitemid 43376630)
25. Begg CB et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA: The Journal of the American Medical Association. 299(2):194-201.
26. Antoniou AC et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 2010;42(10):885-92.
27. Walker LC et al. Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2010;12(6):R102.
28. Engel C et al. Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomark Prev. 2010;19(11):2859-68.
29. Antoniou AC et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008;82(4):937-48.
30. Antoniou AC et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2009;18(22):4442-56.
31. Antoniou AC et al. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007;81(6):1186-200. (Pubitemid 350211449)
32. Antoniou AC et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010;70 (23):9742-54.
33. Wang X et al. Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet. 2010;19(14):2886-97.
34. Gaudet MM et al. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet. 2010;6(10):e1001183.
35. Wacholder S et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010;362(11):986-93.
36. Mitchell G et al. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res. 2006;66 (3):1866-72. (Pubitemid 43259974)
37. Lindström S et al. Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet. 2011;43(3):185-7.
38. Turnbull C et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet. 2010;42(6):504-7.
39. Foulkes WD. Traffic control for BRCA1. N Engl J Med. 2010;362(8):755-6.
40. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med. 2010;362(20):1909-19.
41. Renwick A et al.ATMmutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38(8):873-5. (Pubitemid 44141653)
42. The CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet. 2004;74(6):1175-82.
43. Cybulski C et al. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat. 2007;102 (1):119-22. (Pubitemid 46294966)
44. Bogdanova N et al. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer. 2005;116(2):263-6. (Pubitemid 40967263)
45. Kilpivaara O et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer. 2004;111(4):543-7. (Pubitemid 39045321)
46. Shaag A et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet. 2005;14(4):555-63. (Pubitemid 40277471)
47. Bogdanova N et al. CHEK2 mutation and hereditary breast cancer. J Clin Oncol. 2007;25(19):e26.
48. Heikkinen K et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis. 2006;27(8):1593-9. (Pubitemid 44288048)
49. Bogdanova N et al. Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer. 2008;122(4):802-6.
50. Steffen J et al. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer. 2006;119(2):472-5.
51. Seal S et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38(11):1239-41. (Pubitemid 44646283)
52. Rahman N et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39(2):165-7. (Pubitemid 46184346)
53. Erkko H et al. Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res. 2008;14(14):4667-71.
54. Southey MC et al. A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res. 2010;12(6):R109.
55. Swift M et al. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res. 1976;36(1):209-15.
56. Tavtigian SV et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet. 2009;85(4):427-46.
57. Bell DW et al. Heterozygous germ line hCHK2 Mutations in Li-Fraumeni syndrome. Science. 1999;286(5449):2528-31.
58. Meijers-Heijboer H et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31(1):55-9.
59. Cybulski C et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131-5. (Pubitemid 39532081)
60. Cybulski C et al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet. 2006;43(11):863-6. (Pubitemid 44787112)
61. Weischer M et al. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol. 2007;25(1):57-63. (Pubitemid 350003051)
62. Stolz A et al. The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat Cell Biol. 2010;12(5):492-9.
63. Falck J et al. Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene. 2001;20(39):5503-10. (Pubitemid 32889487)
64. Falck J et al. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature. 2001;410 (6830):842-7. (Pubitemid 32303786)
65. Weischer M et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008;26(4):542-8. (Pubitemid 351264346)
66. Johnson N et al. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet. 2005;366(9496):1554-7. (Pubitemid 41540113)
67. Le Calvez-Kelm F et al. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry (CFR) casecontrol mutation screening study. Breast Cancer Res. 2011;13(1): R6.
68. Lavin MF. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene. 2007;26 (56):7749-58. (Pubitemid 350242462)
69. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 2008;9(10):759-69.
70. Waltes R et al. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet. 2009;84 (5):605-16.
71. Bartkova J et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol. 2008;2 (4):296-316.
72. Akbari MR et al. Germline RAP80 mutations and susceptibility to breast cancer. Breast Cancer Res Treat. 2009;113 (2):377-81.
73. Novak DJ, Sabbaghian N, Maillet P, Chappuis PO, Foulkes WD, Tischkowitz M. Analysis of the genes coding for the BRCA1- interacting proteins, RAP80 and Abraxas (CCDC98), in highrisk, non-BRCA1/2, multiethnic breast cancer cases. Breast Cancer Res Treat. 2009;117(2):453-9.
74. Osorio A et al. Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility. Breast Cancer Res Treat. 2009;113(2):371-6.
75. Nikkilä J et al. Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function. Oncogene. 2009;28(16):1843-52.
76. Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res. 2010;70(19):7353-9.
77. Howlett NG et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297(5581):606-9. (Pubitemid 34815345)
78. Levran O et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet. 2005;37(9):931-3. (Pubitemid 43086147)
79. Levitus M et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet. 2005;37 (9):934-5. (Pubitemid 43086148)
80. Cantor SB et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 2001;105(1):149-60. (Pubitemid 32323924)
81. Cantor S et al. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci USA. 2004;101(8):2357-62. (Pubitemid 38269316)
82. Reid S et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39(2):162-4. (Pubitemid 46184345)
83. Xia B et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39(2):159-61. (Pubitemid 46184344)
84. Erkko H et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446(7133):316-9. (Pubitemid 46426155)
85. Zhang F et al. PALB2 links BRCA1 and BRCA2 in the DNAdamage response. Curr Biol. 2009;19(6):524-9.
86. Zhang F et al. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res. 2009;7(7):1110-8.
87. Xia B et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22(6):719-29.
88. Dray E et al. Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nat Struct Mol Biol. 2010;17(10):1255-9.
89. Tischkowitz M et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA. 2007;104(16):6788-93. (Pubitemid 47175579)
90. Jones S et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324 (5924):217.
91. Tischkowitz MD et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 2009;137(3):1183-6.
92. Vaz F et al. Mutation of the RAD51C gene in a Fanconi anemialike disorder. Nat Genet. 2010;42(5):406-9.
93. Meindl A et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410-4.
94. Akbari MR et al. RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Res. 2010;12(4):404.
95. Zheng Y et al. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010;124(3):857-61.
96. Stoepker C et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet. 2011;43(2):138-41.
97. Kim Y, Smogorzewska A, et al. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet. 2011;43(2):142-6.
98. Crossan GP et al. Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat Genet. 2011;43(2):147-52.
99. Offit K, Garber JE. Time to check CHEK2 in families with breast cancer? J Clin Oncol. 2008;26(4):519-20. (Pubitemid 351264342)
100. Antoniou AC et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86(1):76-83. (Pubitemid 34146344)
101. Byrnes GB, Southey MC, Hopper JL. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res. 2008;10(3):208.
102. Cox A et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 2007;39(3):352-8. (Pubitemid 46328496)
103. Easton DF et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447 (7148):1087-93. (Pubitemid 47014426)
104. Thomas G et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 2009;41(5):579-84.
105. Zheng W et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet. 2009;41 (3):324-8.
106. Hunter DJ et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39(7):870-4. (Pubitemid 47014500)
107. Milne RL et al. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst. 2009;101(14):1012-8.
108. Stacey SN et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2007;39(7):865-9. (Pubitemid 47014497)
109. Stacey SN et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008;40(6):703-6. (Pubitemid 351748861)
110. Ahmed S et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet. 2009;41(5):585-90.
111. Moffa AB, Ethier SP. Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J Cell Physiol. 2007;210(3):720-31. (Pubitemid 46188288)
112. Jia L et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 2009;5(8):e1000597.
113. Ahmadiyeh N et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci USA. 2010;107(21):9742-6.
114. Kraft P, Hunter DJ. Genetic risk prediction-are we there yet? N Engl J Med. 2009;360(17):1701-3.
115. Byrski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28(3):375-9.
116. Bryant HE et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-7. (Pubitemid 40559005)
117. Farmer H et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434 (7035):917-21. (Pubitemid 40559006)
118. Fong PC et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361 (2):123-34.
119. Tutt A et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-44.
120. Audeh MW et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-51.
121. Buisson R et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol. 2010;17(10):1247-54.
122. Lakhani SR et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11(14):5175-80. (Pubitemid 41003703)
123. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48.
124. Galizia E et al. BRCA1 expression in triple negative sporadic breast cancers. Anal Quant Cytol Histol. 2010;32 (1):24-9.
125. Turner NC et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26(14):2126-32. (Pubitemid 46514749)
126. Baldassarre G et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol. 2003;23(7):2225-38. (Pubitemid 36351007)
127. Silver DP et al. Efficacy of neoadjuvant Cisplatin in triplenegative breast cancer. J Clin Oncol. 2010;28(7):1145-53.
128. O'Shaughnessy J et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205-14.
129. Sanofi aventis. Sanofi-aventis-R & D Keys figures 2011; http://en.sanofi-aventis.com/research-innovation/rd-key-figures/rd-key-figures. asp